Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13047212 | 0.91 | TP53 (0.55) | GRM2TP53P2RX7RAB9AALDH1A1 | |
| SCHEMBL13047231 | 0.91 | TP53 (0.55) | GRM2TP53P2RX7RAB9AKDM4E | |
| SCHEMBL1590296 | 0.91 | P2RX7 (0.62) | GRM2TP53P2RX7RAB9AKDM4E | |
| SCHEMBL13047220 | 0.91 | TP53 (0.56) | GRM2TP53P2RX7RAB9AKDM4E | |
| SCHEMBL13047201 | 0.90 | GRM2 (0.59) | GRM2TP53P2RX7RAB9AKDM4E | |
| SCHEMBL13047557 | 0.90 | POLB (0.61) | GRM2TP53P2RX7RAB9AKDM4E | |
| SCHEMBL13046553 | 0.88 | GRM2 (0.57) | GRM2TP53P2RX7RAB9AKDM4E | |
| SCHEMBL13047207 | 0.87 | TP53 (0.55) | TP53P2RX7RAB9AKDM4EMAPK1 | |
| SCHEMBL13047249 | 0.86 | TP53 (0.54) | GRM2TP53RAB9AKDM4EMAPK1 | |
| SCHEMBL13047206 | 0.86 | TP53 (0.54) | GRM2TP53RAB9AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | GRM2 332/4885TP53 4589/4885P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.